A new Ve­ga en­ters the galaxy with bleed­ing dis­or­der an­ti­body set for 2023 tri­al

Biotech in­cu­ba­tor Star Ther­a­peu­tics has launched an­oth­er galaxy-themed drug de­vel­op­er, which next year will test a new an­ti­body in a bleed­ing dis­or­der cur­rent­ly treat­ed by Take­da’s Von­ven­di.

Star lined up a who’s who of biotech ven­ture cap­i­tal firms to line Ve­ga Ther­a­peu­tics’ cof­fers with $40 mil­lion. The funds will bankroll a Phase I study ear­ly next year as the biotech re­cent­ly got the go-ahead from Aus­tri­an au­thor­i­ties, CEO Adam Rosen­thal told End­points News in a pre­view of the un­veil­ing. The biotech will test whether a mon­o­clon­al an­ti­body can treat one of the most com­mon forms of in­her­it­ed bleed­ing dis­or­ders: von Wille­brand dis­ease, or VWD.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER